Abbreviated Name

Liver Full Ref Set App:Yamada (2011)

Lead Investigator

Yamada, Hiro — Wako Diagnostics

Coordinating Investigator

Feng, Ziding — Fred Hutchinson Cancer Center

Involved Investigators

• Feng, Ziding — Fred Hutchinson Cancer Center
• Yamada, Hiro — Wako Diagnostics
• Srivastava, Sudhir — National Cancer Institute

Abstact

No abstract availalbe.

Aims

The specific aim of the proposal is to determine usefulness of the HCC biomarkers in early detection.

Analytic Method

Sensitivity and specificity of AFP, AFP-L3 and DCP assays on the μTASWako i30 will be calculated for the patients using several cutoff values (5%, 7%, 10% etc). Sensitivity by tumor characteristics (stage, size and number) will be evaluated, if the clinical information on the patient characteristics is available.

Outcome

Wako has received new 510(k) clearance for Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) and Des-gamma-carboxy prothrombin (DCP) tests on an innovative μTASWako i30 analyzer from FDA. The AFP-L3 and DCP assayed on an older platform LiBASys have been cleared with indication of use for risk assessment of hepatocellular carcinoma (HCC) in patient at risk for the liver malignancy. Wako believes that early detection of HCC is critical for improving HCC patient outcome. Therefore, Wako is currently seeking collaborative opportunities to retrospectively measure clinical samples using the AFP-L3 and DCP for further determining of effectiveness of the HCC biomarkers in early detection which are collected prospectively during HCC surveillance. The Reference Sample Set in the EDRN biorepository are well characterized and studied. Access to these samples would allow Wako to quickly determine the clinical effectiveness of AFP-L3 and DCP in detecting early HCC

Publications

• No publications available at this time for this protocol.

Biomarkers

• AFP
• AFP-L3
• DCP

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Start Date

Jul 20 2011

Estimated Finish Date

Oct 20 2011

Finish Date

Nov 30 2011

Protocol ID

334

Protocol Type

Reference Set

Field of Research

Proteomics

Collaborative Group

G.I. and Other Associated Cancers Research Group

Cancer Types

• Liver cell carcinoma

Phased Status

2